We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration
News

Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration

Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration
News

Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eidogen-Sertanty, Inc. has announced that they have established collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of small molecules for anti-inflammatory indications.

Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of synthetically tractable and drug-like compounds with predicted activity against a target of interest to Kalypsys.

The collaboration builds upon Kalypsys’ existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).

"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys’ small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.

"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.

Advertisement